Topics

Luye Pays $5 Million Upfront for China Rights to PharmaMar's SCLC Treatment

05:13 EDT 30 Apr 2019 | ChinaBio Today

Luye Pharma in-licensed greater China rights to PharmaMar's lurbinectedin (Zepsyre®) as a treatment for small cell lung cancer (SCLC). Luye will make an up-front payment of $5 million followed by additional regulatory and sales milestones, as well as double-digit royalties. If lurbinectedin is approved for other indications, Luye will make additional payments. Lurbinectedin is an inhibitor of RNA polymerase II, which is essential for the transcription process. PharmaMar, a Madrid biopharma, is developing the drug in tumors with transcription addiction. More details....

Stock Symbols: (HK: 2186) (MSE: PHM)

Share this with colleagues:

Original Article: Luye Pays $5 Million Upfront for China Rights to PharmaMar's SCLC Treatment

NEXT ARTICLE

More From BioPortfolio on "Luye Pays $5 Million Upfront for China Rights to PharmaMar's SCLC Treatment"

Quick Search

Relevant Topic

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...